SBIR/STTR Research Award
Non invasive risk assessment tool for pediatric heart failure
Award amount
$153,531Program and phase
STTR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CORAMIR BIOMEDICAL, INC.
- Proposal award date
- 2017-09-01
- Contract end date
- 2019-02-28
- UEI
- R5LWUN6RJEQ3
- Solicitation number
- PA16-303
- Topic code
- NHLBI
Research abstract
ABSTRACT
Heart Failure HF in pediatric patients is a devastating disease that is difficult to evaluate even with
invasive hospital procedures Importantly and unique to the pediatric population approximately of
pediatric HF patients spontaneously recover normal heart function within year of diagnosis Unfortunately
there is no reliable clinical parameter or biomarker that allows pediatric cardiologists to correctly predict which
of their HF patients will recover normal heart function without surgical intervention forcing clinicians to place
their these children on transplant lists even though surgical intervention would be unnecessary in some cases
Offering a potential solution to this problem a recent study performed at the University of Colorado Denver has
identified unique expression signatures of microRNAs found in circulating blood that correlate with a
subpopulation of pediatric HF patients who recover ventricular function without surgical intervention It is the
objective of this Phase I project to complete initial proof of concept experiments related to the development of
a commercial test based on the measurement of these circulating miRNAs The work proposed to complete
this project is designed to provide the groundwork for a prospective Phase II trial By establishing and
validating the test protocols with control samples this project will create the basis for a test that can then be
evaluated in a subsequent prospective study designed to tests newly diagnosed pediatric HF patients and
follow their treatment outcomes The successful development of a non invasive test for pediatric HF patients
would have significant patient and commercial value By providing clinicians with a non invasive risk
stratification tool for pediatric patients with HF a test of this kind would help clinicians patients and families
understand health related prognosis for appropriate long term planning reduce the number of invasive
procedures performed on these compromised patients prevent unnecessary transplantations improving
survival for decades beyond the current year lifespan of a transplanted heart and decrease health
care expenditures associated with cardiac transplantation NARRATIVE
A recent study performed at the University of Colorado Denver has identified unique expression signatures
of microRNAs found in circulating blood that correlate with a subpopulation of pediatric Heart Failure patients
who recover ventricular function without a need for transplantation It is the objective of this Phase I project to
complete proof of concept experiments related to the development of a biomedical test based on the
measurement of these circulating miRNAs that will help clinicians risk stratify their patients
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications